A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954 · Recruiting

Last updated 2026-05-28

This study is testing different doses of the medicine NNC0662-0419 to see how well it lowers blood sugar in adults with type 2 diabetes.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 270 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-04 · est. completion 2027-10

Where 63 sites · Croatia, Hungary, Japan, Poland, Portugal, Slovakia, South Korea, Spain, Thailand, United States

What this study is testing ClinicalTrials.gov NCT07415954 ↗

Description as written by the study sponsor.

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

Treatments tested

NNC0662-0419 Drug

NNC0662-0419 will be administered subcutaneously.
Semaglutide Drug

Semaglutide will be administered subcutaneously.
Placebo Drug

Placebo will be administered subcutaneously.

Main thing measured	Change in glycated haemoglobin (HbA1c) (week 16)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07415954 ↗